[go: up one dir, main page]

AR059722A1 - Aminas inhibidoras de renina. composiciones farmaceuticas y usos. - Google Patents

Aminas inhibidoras de renina. composiciones farmaceuticas y usos.

Info

Publication number
AR059722A1
AR059722A1 ARP070100882A ARP070100882A AR059722A1 AR 059722 A1 AR059722 A1 AR 059722A1 AR P070100882 A ARP070100882 A AR P070100882A AR P070100882 A ARP070100882 A AR P070100882A AR 059722 A1 AR059722 A1 AR 059722A1
Authority
AR
Argentina
Prior art keywords
alkyl
ch2ch2
ch2ch2ch2
independently selected
cyclopropyl
Prior art date
Application number
ARP070100882A
Other languages
English (en)
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of AR059722A1 publication Critical patent/AR059722A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

Composiciones farmacéuticas que contienen uno o más de estos compuestos y especialmente su utilizacion como inhibidores de renina. Reivindicacion 1: Un compuesto de la formula (1) donde X representa CH, N+, -O-, W representa un piridinilo o un tiazolilo para-sustituido; V representa -CH2CH2CH2-, -CH2CH2-A-, -CH2-A-CH2, -A-CH2CH2-,CH2CH2CH2CH2-, -A-CH2CH2CH2-, -CH2-A-CH2CH2-, -CH2CH2-A-CH2-, -CH2CH2CH2-A-, -A-CH2CH2-B-, -CH2CH2CH2CH2CH2-, -A-CH2CH2CH2CH2-, -CH2-A-CH2CH2CH2, -CH2CH2-A- CH2CH2, -CH2CH2CH2-A-CH2, -CH2CH2CH2CH2-A-, -A-CH2CH2CH2-B-, -CH2-A-CH2CH2-B-, -A-CH2CH2-B-CH2-, -A-CH2CH2CH2-B-CH2-, -CH2-A-CH2CH2CH2-B-, -O-CH2-Q-, donde Q está unido al grupo U de formula (1), o un pirrolidinilo de la formula (2), U representa arilo no sustituido; arilo mono-, di-, tri- o tetra-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo C1-7, -CF3, halogeno, e hidroxi-alquilo C1-7 o un heteroarilo de cinco miembros con dos heteroátomos seleccionados independientemente entre nitrogeno, oxigeno y azufre, donde dicho radical de heteroarilo está opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo C1-7, alcoxi C1-7, -CF3, -OCF3, y halogeno; Q representa un heteroarilo de cinco miembros con dos o tres heteroátomos seleccionados independientemente entre O y N; A y B representan independientemente entre sí -O- o -S-; R1 representa alquiloC1-7 o cicloalquilo; R2 representa halogeno o alquiloC1-7, R3 representa hidrogeno, halogeno, alquilo C1-7, alcoxi C1-7, o -CF3 y R4 representa hidrogeno; alquil C1-7-O-(CH2)0-4-CH2-; CF3-O-(CH2)0-4-CH2-; R'2N-(CH2)0-4-CH2, donde R' se selecciona independientemente del grupo formado por hidrogeno, alquilo C1-7 (opcionalmente sustituido con uno a tres fluor), ciclopropilo (opcionalmente sustituido con uno a tres fluor), ciclopropil-aIquilo C1-7 (opcionalmente sustituido con uno a tres fluor), y -C(=O)-Rö donde Rö es alquilo C1-4, alcoxi C1-4, -CF3, -CH2-CF3, o ciclopropilo; o R5-C(=O)-(O)0-1-(CH2)0-4-, donde R5 es alquilo C1.4, aIcoxi C1-4, o ciclopropilo; y sus sales.
ARP070100882A 2006-03-03 2007-03-02 Aminas inhibidoras de renina. composiciones farmaceuticas y usos. AR059722A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IB2006050678 2006-03-03

Publications (1)

Publication Number Publication Date
AR059722A1 true AR059722A1 (es) 2008-04-23

Family

ID=38459419

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100882A AR059722A1 (es) 2006-03-03 2007-03-02 Aminas inhibidoras de renina. composiciones farmaceuticas y usos.

Country Status (16)

Country Link
US (1) US20090088457A1 (es)
EP (1) EP2029542A2 (es)
JP (1) JP2009528341A (es)
KR (1) KR20080100382A (es)
CN (1) CN101395135A (es)
AR (1) AR059722A1 (es)
AU (1) AU2007220149A1 (es)
BR (1) BRPI0708487A2 (es)
CA (1) CA2642424A1 (es)
IL (1) IL193831A0 (es)
MA (1) MA30292B1 (es)
MX (1) MX2008011183A (es)
NO (1) NO20084055L (es)
TW (1) TW200800940A (es)
WO (1) WO2007099509A2 (es)
ZA (1) ZA200808419B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571595A (en) * 2006-03-08 2010-06-25 Actelion Pharmaceuticals Ltd New amines
US8129538B1 (en) 2007-03-28 2012-03-06 Takeda Pharmaceutical Company Limited Renin inhibitors
CA2688057A1 (en) 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
EP2188256A4 (en) * 2007-08-07 2010-12-15 Merck Frosst Canada Ltd INHIBITORS OF THE RENIN
WO2009023964A1 (en) 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
WO2009087649A1 (en) * 2007-10-15 2009-07-16 Cadila Healthcare Limited Renin inhibitors
JP4790871B2 (ja) 2008-05-05 2011-10-12 メルク フロスト カナダ リミテツド レニン阻害剤としての３，４−置換ピペリジン誘導体
WO2013088452A2 (en) 2011-11-11 2013-06-20 Sun Pharma Advanced Research Company Ltd. Quinoline derivatives as renin inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003229746A1 (en) * 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Novel tetrahydropyridine derivatives as renin inhibitors
CN1863773A (zh) * 2003-10-09 2006-11-15 埃科特莱茵药品有限公司 四氢吡啶衍生物
WO2005054244A2 (en) * 2003-12-05 2005-06-16 Actelion Pharmaceuticals Ltd Azabicyclooctene and other tetrahydropyridine derivatives with a new side-chain
CN101010323B (zh) * 2004-08-25 2010-06-16 埃科特莱茵药品有限公司 作为肾素抑制剂的双环壬烯衍生物

Also Published As

Publication number Publication date
CA2642424A1 (en) 2007-09-07
ZA200808419B (en) 2009-12-30
CN101395135A (zh) 2009-03-25
WO2007099509A2 (en) 2007-09-07
JP2009528341A (ja) 2009-08-06
WO2007099509A3 (en) 2007-12-21
TW200800940A (en) 2008-01-01
EP2029542A2 (en) 2009-03-04
US20090088457A1 (en) 2009-04-02
MX2008011183A (es) 2008-09-09
MA30292B1 (fr) 2009-03-02
NO20084055L (no) 2008-10-09
BRPI0708487A2 (pt) 2011-05-31
IL193831A0 (en) 2009-08-03
KR20080100382A (ko) 2008-11-17
AU2007220149A1 (en) 2007-09-07

Similar Documents

Publication Publication Date Title
AR059722A1 (es) Aminas inhibidoras de renina. composiciones farmaceuticas y usos.
AR076264A1 (es) Triazolopiridinas sustituidas y analogos de estas
CY1117862T1 (el) Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης
AR111009A1 (es) INHIBIDORES DE INTEGRINA avb6
AR077598A1 (es) Compuestos heterociclicos fusionados como modulares de canales ionicos
AR096979A1 (es) Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
AR058120A1 (es) Derivados de bencimidazol sustituidos con cromano, una composicion farmaceutica que los contiene y el uso de los mismos en el tratamiento de una enfermedad mediada por la inhibicion de la bomba de acido
PE20121431A1 (es) Derivados de pirimidina como inhbidores de la enzima cinasa ptk2
AR076754A1 (es) Dihidropirimidinas y proceso de obtencion de las mismas
AR079334A1 (es) Derivados de oxazin amino
AR082508A1 (es) Derivados de bencimidazoles utiles como inhibidores de prostaglandina esintasa-1 microsomica
AR089774A1 (es) Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR061994A1 (es) Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden
CO6241108A2 (es) Derivados de pirrolopiridina y sus uso como inhibidores de bace
AR070459A1 (es) Derivados de 2-aza-biciclo- [2,2,1] heptano
PE20191020A1 (es) Compuestos quimicos
AR053652A1 (es) Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas
WO2010005534A3 (en) Proteasome inhibitors for selectively inducing apoptosis in cancer cells
AR054766A1 (es) Amidas derivadas de acidos piperidin carboxilicos y su uso como ingredientes activos en la preparacion de composiciones farmaceuticas
AR059284A1 (es) Derivados de aminas secundarias
AR075332A1 (es) Dionas ciclicas como herbicidas
AR091519A1 (es) Inhibidores pirrolopirazona de tanquirasa
CO6270309A2 (es) Inhibidores tetrahidropiranocromeno de gamma secretasa
AR080703A1 (es) Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma.
ECSP088805A (es) 2-(piridin-2-il)-pirimidinas como fungicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure